Optinose to Report Third Quarter 2017 Financial Results and Operational Highlights on November 27, 2017

YARDLEY, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Optinose OPTN, a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that the Company will report its third quarter 2017 financial results and recent operational highlights on Monday, November 27, 2017.

About Optinose®
Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for by ear, nose and throat (ENT) and allergy specialists. The Company's first two products rely on our patented Exhalation Delivery Systems (EDS), which are capable of deep intranasal deposition of medication. These exhalation delivery systems enable the creation of products with potential for meaningful new clinical benefits. Optinose developed its first product, Onzetra^® Xsail^® (sumatriptan nasal powder), through the completion of Phase 3 and subsequently out-licensed the product to Otsuka Pharmaceutical Co., Ltd. Onzetra Xsail received FDA approval and was launched in the U.S. in 2016. The Company's second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in patients 18 years of age and older and is in development for the treatment of chronic sinusitis. Subsequent Optinose pipeline products will aim to serve the needs of patients treated by ENT and allergy specialists and are expected to include products using EDS as well as other technologies. The Company is also currently engaged in the early development of products for neurologic orphan diseases for which the "nose-to-brain" application of an EDS may enable improved treatment. This includes OPN-300 (autism and others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway.  To learn more, please visit www.optinose.com.

Optinose Media Contact
Kate Traynor, Sloane & Company
Ktraynor@sloanepr.com
212.446.1871